


THE UNIVERSITY OF TEXAS

MDAnderson
~~Cancer~~ Center

Making Cancer History®

ANGIO
2014



The 16th International Symposium on Anti-Angiogenic Therapy:

*Recent Advances and Future Directions
in Basic and Clinical Cancer Research*

February 6–8, 2014

Hyatt Regency La Jolla • 3777 La Jolla Village Drive • San Diego, California

www.antiangio2014.com

For Information and Poster Submission Form

Program Overview

The field of anti-angiogenic therapy is quite complicated with various results with individual agents in different disease types. In fact, the efficacy of such agents in the advanced setting is different from that of an early stage in the adjuvant setting. In addition to learning more about the efficacy and appropriate use of these agents, it is also important for health care providers to understand new toxicities that have been recognized in association with the use of anti-angiogenic agents.

This symposium will provide a comprehensive overview of the appropriate use of anti-angiogenic therapy in patients with solid malignancies. In addition, this symposium will review the appropriate use of anti-angiogenic agents and allow the learner to recognize toxicity and potential biomarkers.

The main area of feedback focused on biomarkers and the appropriate use of therapy. This is an inherent challenge as we do not have any biomarkers that are validated. However we will continue to scan the literature and seek speakers who can address the issue of biomarkers and patient selection. We will also seek speakers and discuss resistance pathways, which overlap with the above issues.

Educational Objectives

After attending the symposium, participants should be able to

- Summarize available data from clinical trials that support the use of currently available anti-angiogenic agents as monotherapy or in combination with other therapeutic modalities, for appropriate clinical decisions (*Knowledge, Competence, Performance, Patient Outcomes*);
- Explain relevant aspects of vascular biology; define angiogenesis and its relevance to the treatment of cancer (*Knowledge, Competence*);
- Outline the rationale for the development of anti-angiogenic agents, why angiogenic signaling pathways are targets for inhibition, and how resistance mechanisms function (*Knowledge, Competence*);
- Discuss and apply preclinical and clinical data on emerging anti-angiogenic agents to improve safety, efficacy, and ultimately, quality of patient care (*Knowledge, Competence, Performance, Patient Outcomes*);
- Gather highlights on current controversies and emerging strategies in the field, for changes to clinical practice and, if necessary, further discussion or research (*Knowledge, Competence, Performance, Patient Outcomes*).

Target Audience

This symposium is designed for medical, surgical, and radiation oncologist, pharmacists, other providers of cancer care (PAs, RNs, etc.), and research scientists who have an interest in the biology, diagnosis, and treatment of cancer, as well as those who diagnose and treat patients with nonmalignant vascular diseases, such as arthritis and retinal neovascularization. As new and emerging data on anti-angiogenic therapy is presented at this symposium every year, it is necessary for this audience to be made aware of these findings so they can be utilized in their clinical practice.

Educational Methods

Lectures – Panel Discussions – Question and Answer – Poster Session

Evaluation

A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

Accreditation/Credit Designation

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 14.00 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Certificates and Attendance Verification Certificates

Certificates awarding *AMA PRA Category 1 Credit*[™] or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a *CME Verification Form*.

Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

Planning Committee

Lee M. Ellis, MD

Professor of Surgical Oncology & Molecular & Cellular Oncology
William C. Liedtke, Jr., Chair in Cancer Research
The University of Texas MD Anderson Cancer Center
Houston, Texas

Robert S. Kerbel, PhD

Canada Research Chair in Tumor Biology, Angiogenesis and Antiangiogenic Therapy
Senior Scientist, Biological Sciences Platform
Sunnybrook Research Institute/Odetta Cancer Centre
Professor,
University of Toronto
Toronto, Ontario, Canada

Axel Grothey, MD

Professor of Oncology, Mayo Clinic
Division of Medical Oncology
Rochester, Minnesota

Helen X. Chen, MD

Senior Investigator in Cancer Therapy Evaluation Program
National Cancer Institute
Rockville, Maryland

George W. Sledge, Jr., MD

Professor of Medicine
Chief, Division of Oncology
Stanford University School of Medicine
Stanford, California

POSTER SUBMISSION/SESSION:

The symposium will feature a poster session where academics and investigators from the industry present angiogenesis-related data from both clinical trials and laboratory research. Trainees are especially encouraged to present their research. Accepted posters will be displayed with ample time for viewing and discussions.

All symposium participants, including members of industry, are encouraged to present research data as part of the poster session.

The deadline for submitting poster applications is Friday, December 6, 2013.


Please check the website for more information and the submission form at www.antiangio2014.com.

Travel Fellowship Awards

A limited number of travel fellowships will be available to trainees submitting a poster. Please check the appropriate box on the registration form to apply for a travel fellowship, and have your dean or department chair sign the registration form confirming you are a trainee.

The deadline for applying for a travel fellowship is Friday, December 6, 2013.

Program



Wednesday, February 5, 2014

3:00–7:00 p.m. Registration

Thursday, February 6, 2014

7:30–8:00 a.m. Registration/Continental Breakfast

Session I: Basic Biology and Preclinical Data

Moderator: Lee M. Ellis, MD

8:00–8:30 **Opening Remarks/Overview**
Lee M. Ellis, MD

8:30–8:55 **Complexities in VEGF Signaling:
Can We Really Tackle This Problem With Targeted Therapy?**
Luisa Iruela-Arispe, PhD

8:55–9:20 **Molecular Determinants of Vascular Angiocrine
Heterogeneity for Tumor Targeting**
Shahin Rafii, MD

9:20–9:45 **Notch Ligand Inhibitors Target Tumor Angiogenesis by
Diverse Mechanisms**
Jan Kitjewski, PhD

9:45–10:10 **Vessel Co-option: An Under-appreciated Phenomenon
With Profound Consequences for the Clinical Translation
of Anti-Angiogenic Therapy**
Andrew R. Reynolds, PhD

10:10–10:35 Break

10:35–11:00 **What Does Anti-VEGF/VEGFR Therapy Actually Do?**
Harold F. Dvorak, MD

11:00–11:15 **Abstract #1**

11:15–11:40 **Antibody Drug Conjugates Targeting the Vasculature**
Brad St. Croix, PhD

11:40–12:05 p.m. **Control of Tumor Vascularization and Vascular
Metastasis by Hypoxia Inducible Factor 1**
Gregg Semenza, MD, PhD

12:05–1:05 Lunch

Session II—Resistance Mechanisms

Moderator: Robert S. Kerbel, PhD

1:05–1:30

PK Mediated Reversible Resistance to Anti-Angiogenic TKIs
Robert S. Kerbel, PhD

1:30–1:55

**Autophagy-mediated Resistance to Cytotoxic Drugs
and Bevacizumab in Colorectal Cancer:
Preclinical and Clinical Findings**
Peter J. O'Dwyer, MD

1:55–2:10

Abstract #2

2:10–2:35

**Mechanisms and Therapeutic Circumvention of
Adaptive-evasive Resistance to Anti-Angiogenic
Cancer Therapy**
Douglas Hanahan, PhD

2:35–3:00

Break

3:00–4:30

Biomarker Programs From Industry (Non CME)
Bayer Michael Teufel, PhD
Genentech/Roche Priti Hedge, PhD
GSK Lini Pandite, MD
Pfizer Jean-Francois Martini, PhD
Sanofi/Regeneron Michael Andria, PharmD.

4:30–6:00 p.m.

Poster Reception

Friday, February 7, 2014

7:30–8:00 a.m. Registration/Continental Breakfast

Session III: Early Drug Development

Moderators: Helen X. Chen, MD; George W. Sledge, Jr., MD

8:00–8:15

Phase 1 Drug 1
Michael S. Gordon, MD

8:15–8:30

Phase 1 Drug 2
Lee S. Rosen, MD

8:30–8:45

Abstract #3

8:45–9:00

**FOL FOX, Bevacizumab, and PD-L1 Antibody
Combination Therapy**
S. Gail Eckhardt, MD

9:00–9:25

**Combination of Targeted Agents:
Are There Therapeutic Windows?**
Helen X. Chen, MD

9:25–9:50

Break

Session IV: Controversies and Emerging Strategies

Moderators: Helen X. Chen, MD; Michael S. Gordon, MD

- 9:50–10:15 **VEGF-targeted Therapy in the Maintenance Setting**
Axel Grothey, MD
- 10:15–10:50 **What Next?**
George W. Sledge, Jr., MD
- 10:50–11:15 **VEGF as a Biomarker For Immunotherapy and Implications for Combination Strategies**
Howard Kaufman, MD
- 11:15–11:50 **Combination of Anti-Angiogenic Therapies with Check-point Inhibitors**
Glenn Dranoff, MD
- 11:50–12:30 p.m. Lunch

Session V: Clinical Trial Results

Moderator: Axel Grothey, MD

- 12:30–12:55 **It's Not Dead Yet: The Checkered History of Anti-Angiogenic Therapy in Breast Cancer. Can We Find a Way Forward?**
Kathy D. Miller, MD
- 12:55–1:10 **Abstract #4**
- 1:10–1:35 **Anti-Angiogenic Agents Post Sorafenib in Advanced HCC: The Bar is Higher Than It Looks**
R. Kate Kelley, MD
- 1:35–2:00 Break
- 2:00–2:25 **Anti-Angiogenic TKIs for Thyroid Cancer: Is VEGFR Really the Target?**
Steven I. Sherman, MD
- 2:25–2:50 **Anti-Angiogenic Therapy for the Treatment of Gynecologic Malignancies**
Robert Allen Burger, MD
- 2:50–3:15 **How to Prioritize Therapies for Renal Cell Carcinoma**
Michael B. Atkins, MD
- 3:15–3:45 **Anti-Angiogenic Therapy for Gastric Cancer**
Charles S. Fuchs, MD
- 4:00 p.m. Adjourn


Saturday, February 8, 2014

7:30–8:00 a.m. Registration/Continental Breakfast

Session V: Clinical Trial Results

Moderator: Michael S. Gordon, MD

- 8:00–8:05 Introduction
Michael S. Gordon, MD
- 8:05–8:30 **Anti-Angiogenic Therapy for Glioblastoma: Is Full Approval Justified?**
David Reardon, MD
- 8:30–8:55 **Anti-Angiogenic Therapy for the Treatment of NETS**
George Fisher, MD
- 8:55–9:10 **Abstract #5**
- 9:10–9:35 **Anti-Angiogenic Therapy for the Treatment of Lung Cancer**
Alex A. Adjei, MD, PhD
- 9:35–10:00 **Anti-Angiogenic Therapy for the Treatment of CRC: Have We Hit the Ceiling?**
Axel Grothey, MD
- 10:00 **Closing Remarks**
- 10:10 a.m. Adjourn



Faculty

Alex A. Adjei, MD, PhD

Senior Vice-President
Clinical Research
Professor and Chairman
Department of Medicine
Katherine Anne Gioia Chair
in Medicine
Roswell Park Cancer Institute
Buffalo, New York

Luisa Iruela-Arispe, PhD

Professor and Vice Chair
Department of Molecular,
Cell and Developmental Biology
UCLA
Los Angeles, California

Michael B. Atkins, MD

Deputy Director
Georgetown-Lombardi
Comprehensive Cancer Center
Washington, DC

Robert Allen Burger, MD

Professor
Surgical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Helen X. Chen, MD

Senior Investigator in
Cancer Therapy
Evaluation Program
National Cancer Institute
Rockville, Maryland

Glenn Dranoff, MD

Professor
Department of Medicine
Dana Farber Cancer Institute
Boston, Massachusetts

Harold F. Dvorak, MD

Mallinckrodt Distinguished
Professor of Pathology
Beth Israel Deaconess
Medical Center
Boston, Massachusetts

S. Gail Eckhardt, MD

Professor and Division Head
Medical Oncology
Stapp Harlow Chair in
Cancer Research
University of Colorado Denver
Aurora, Colorado

Lee M. Ellis, MD

Professor of Surgical Oncology
& Molecular & Cellular Oncology
William C. Liedtke, Jr.
Chair in Cancer Research
The University of Texas
MD Anderson Cancer Center
Houston, Texas

George A. Fisher, MD, PhD

Professor of Medicine
Stanford University
Medical School
Stanford, California

Charles S. Fuchs, MD

Professor
Department of Medicine
Dana-Farber Cancer Institute
Boston, Massachusetts

Michael S. Gordon, MD

Medical Oncology
Pinnacle Oncology Hematology
Scottsdale, Arizona

Axel Grothey, MD

Professor of Oncology
Mayo Clinic College of Medicine
Rochester, Minnesota

Douglas Hanahan, PhD

Director, Swiss Institute for
Experimental Cancer Research
(ISREC)
Lausanne, Switzerland

Howard L. Kaufman, MD

Professor of Surgery &
Immunology & Microbiology
Rush University Medical Center
Chicago, Illinois

R. Kate Kelley, MD

Assistant Professor
Department of Medicine
Helen Diller Family
Comprehensive Cancer Center
University of California
San Francisco, California

Robert S. Kerbel, PhD

Canada Research Chair in
Tumor Biology,
Angiogenesis and
Antiangiogenic Therapy
Senior Scientist,
Biological Sciences Platform
Sunnybrook Research Institute/
University of Toronto
Toronto, Ontario, Canada

Jan Kitajewski, PhD

Charles and Marie Robertson
Professor
Department of Pathology
& Cell Biology
Columbia University
New York, New York

Kathy D. Miller, MD

Ballve Lantero Scholar
in Oncology
Associate Professor
Department of Medicine
Indiana University
Melvin and Bren Simon
Cancer Center
Indianapolis, Indiana

Peter J. O'Dwyer, MD

Professor of Medicine
Medical Oncology
Director, Developmental
Therapeutics Program
Abramson Cancer Center
Philadelphia, Pennsylvania

Shahin Rafii, MD

Arthur B. Belfer Professor of
Genetic Medicine
Director Ansary Stem Cell Institute
Weill Cornell Medical College
New York, New York

David Reardon, MD

Clinical Director, Center for Neuro-Oncology
Associate Professor of Medicine
Dana-Farber Cancer Institute
Boston, Massachusetts

Andrew R. Reynolds, PhD

Team Leader
Tumour Biology Team
The Breakthrough Breast Cancer
Research Centre
The Institute of Cancer Research
London, United Kingdom

Lee S. Rosen, MD

Professor of Clinical Medicine
UCLA Division of Hematology-Oncology
University of California
Los Angeles, California

Gregg L. Semenza, MD, PhD

Professor
Department of Pediatrics, Medicine,
Oncology & Radiation Oncology
Johns Hopkins University
School of Medicine
Baltimore, Maryland

Steven I. Sherman, MD

Chair & Professor
Endocrine Neoplasia & HD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

George W. Sledge, Jr., MD

Ballve-Lantero Professor of Oncology
Professor of Medicine
Chief, Division of Oncology
Stanford University School of Medicine
Stanford, California

Brad St. Croix, PhD

Mouse Cancer Genetics Program
Head, tumor Angiogenesis Section
Center for Cancer Research
National Cancer Institute
Frederick, Maryland

Registration Information

On-site registration will be open from 3:00-7:00 p.m. on Wednesday, February 5, 2014, and at 7:30 a.m. on Thursday, February 6. The conference will begin at 8:00 a.m. on Thursday, February 6, and adjourn at 10:10 a.m. on Saturday, February 8. Advance registration is encouraged as space and materials are limited. Please see registration form for applicable fees.

The deadline for advance registration is January 17, 2014.

There are three ways to register:

- Mail to: CME/Conference Management—Unit 1381, The University of Texas MD Anderson Cancer Center, P.O. Box 301439, Houston, TX 77230-1439
- Fax to: 713-794-1724
- On-line at www.mdanderson.org/conferences

We accept the following forms of payment:

- Check (payable through U.S. banks only)
- Money Order
- Credit Cards (MasterCard, VISA, and American Express)
- Cash (on-site registration only)

A receipt and confirmation letter will be sent to you within ten working days of receipt of your fee.

The full conference registration fee includes the tuition, breaks, lunch, and poster reception.

Refund/Cancellation Policy:

The registration fee, minus a \$50 administrative handling fee, is refundable if a written request is received on or before January 17, 2014. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.

The Department of CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified either by mail, e-mail, or the contact numbers as given on the registration form.

In case of activity cancellation, liability of the Department of CME/Conference Management is limited to the registration fee. CME/Conference Management will refund the full registration fee. The Department of CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.

For additional information, contact CME/Conference Management at 713-792-2223 or toll free at 866-849-5866.

Special Assistance

Contact the Department of CME/Conference Management at 713-792-2223 or toll free at 866-849-5866 if you have any special dietary or ADA accommodation needs.

Accommodations

- A block of rooms has been reserved for conference attendees at the **Hyatt Regency La Jolla**, 3777 La Jolla Village Drive, San Diego, California.
- Early hotel reservation is suggested.
- The hotel phone number is 858-552-1234.
- When you make reservations be sure to mention the MD Anderson 16th International Symposium on Anti-Angiogenic Agents to be assured of receiving the special meeting rate of \$220.00 single or double occupancy. Please add 12.5% California state and local taxes. Reservations and deposits received after January 3, 2014 will be confirmed if space is available and at current hotel published guest room rates.

Ground Transportation

The hotel is approximately 20 miles from the San Diego International Airport. Taxi rates are approximately \$45 one way.

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration.

CONFERENCE REGISTRATION - 0639/110840

The 16th International Symposium on Anti-Angiogenic Therapy:

Recent Advances and Future Directions in Basic and Clinical Cancer Research, February 6–8, 2014

THIS IS NOT A SELF-MAILER

ADDRESS TO:

The 16th International Symposium on Anti-Angiogenic Therapy:
Recent Advances and Future Directions in Basic and Clinical Cancer Research

Department of CME/Conference Management—Unit 1381
The University of Texas MD Anderson Cancer Center
PO Box 301439, Houston, TX 77230-1439

or fax to 713-794-1724

Make check or money order payable to:

The University of Texas MD Anderson Cancer Center

REGISTRATION FEES

- ☐ Postmarked by 1/17/14.....\$ 275.00
- ☐ Postmarked after 1/17/14.....\$ 325.00

Trainees:

- ☐ Postmarked by 1/16/13.....\$ 100.00
- ☐ Postmarked after 1/16/13.....\$ 150.00
- ☐ Trainee Submitting Poster\$ 50.00
- ☐ Application for a Travel Fellowship

Department Chair should verify Trainee status by signing below:

Registration also available on-line
www.antiangio2014.com

Last Name	First	MI	Highest Degree
Department (include box no.)		Specialty	
Institution		Physician	☐ Yes ☐ No
Street	City	State/Foreign Country/Zip or Mail Code	
Daytime Phone (with area code)	Cell Phone (with area code)	Fax (with area code)	
E-mail Address (please print)			
Emergency Contact	Phone (with area code)	Charge the following: ☐ VISA ☐ MasterCard ☐ American Express	
Credit Card Holder Name (First/Last)		Credit Card Holder Billing Address & ZIP Code	
Credit Card Number		Expiration Date	
MD Anderson Interdepartmental Transfer (IDT) No.: *Fund Group 90 will not be accepted			
Business Unit	Department	Fund Group*	Fund Type
Authorized Signature REQUIRED for credit card or IDT		MD Anderson Employee ID No. (REQUIRED)	
IDT Approver Name (First/Last) please print		IDT Approver E-mail	

Department of CME/Conference Management - Unit 1381
The University of Texas MD Anderson Cancer Center
176700/110846/30070639
PO Box 301439
Houston, TX 77230-1439

Non-Profit Org.
U.S. Postage
PAID
Houston, TX
Permit No. 7052